A phase I open-label study of the safety and pharmacokinetics of recombinant human interleukin-21 (rIL-21) in subjects with metastatic melanoma or metastatic renal cell carcinoma
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2007
At a glance
- Drugs Denenicokin (Primary)
- Indications Malignant melanoma; Renal cancer
- Focus Adverse reactions
- 06 Sep 2005 New trial record.